Focus on leveraging the power of AI to expand the therapeutic index of existing portfolio
BRANFORD, CT December 11, 2018, InveniAI® Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries, is pleased to announce it has entered a collaboration agreement with Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) to harness the power of AI and ML for drug discovery. Through this collaboration, Kyowa Hakko Kirin, a life sciences company with a focus on new biologics and medicines for unmet medical needs, will leverage InveniAI’s platform – AlphaMeld™ – to maximize portfolio value through the re-innovation of an existing therapeutic pipeline into new disease indications.
Mitsuo Satoh, Ph.D., Executive Officer, Vice President, Head, R&D Division of Kyowa Hakko Kirin said, “As we seek to fulfill our business vision to bring innovative treatments to patients faster, we very much expect that InveniAI’s platform, will not only enable us to identify alternate therapeutic value for our portfolio at an unprecedented speed but also capitalize on our existing investment by reducing the time to market, clinical cost of development and enhancing the probability of clinical success.”
Krishnan Nandabalan, Ph.D., CEO and President of InveniAI said, “We are extremely pleased to initiate this collaboration to build on Kyowa Hakko Kirin’s clinically rich pipeline. AlphaMeld has industrialized the process of drug re-innovation by enabling the identification of complex associations between drugs/mechanisms and disease indications. The platform is patient-validated where multiple drug concepts have progressed through to human proof of clinical development.”
Under the terms of the collaboration, InveniAI will receive an upfront payment as well as development milestones and commercialization payments. Financial details are not disclosed.
About Kyowa Hakko Kirin
Kyowa Hakko Kirin Co., Ltd. is a research-based life sciences company, with special strengths in biotechnologies. In the core therapeutic areas of oncology, nephrology and immunology/allergy, Kyowa Hakko Kirin leverages leading-edge biotechnologies centered on antibody technologies, to continually discover innovative new drugs and to develop and market those drugs worldwide. In this way, the company is working to realize its vision of becoming a Japan-based global specialty pharmaceutical company that contributes to the health and wellbeing of people around the world.
You can learn more about the business at www.kyowa-kirin.com
InveniAI, a wholly owned subsidiary and technology spin-out of BioXcel Corporation, has pioneered the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries. InveniAI is leveraging AI and ML to harness petabytes of disparate data sets to recognize and unlock value. Our domain expertise spans AI-based innovation monitoring to AI-based drug discovery. Our numerous industry collaborations with Big Pharma, Specialty Pharma, and BioPharma, showcase the value of our platform in recognizing complex patterns and associations to complement and amplify human expertise. We continue to collaborate with our industry partners to address cutting-edge problems across the value chain from internal to external innovation and to compliment corporate decision making. We are headquartered in Branford, CT, USA.
Anita Ganjoo, Corporate Communications
T: +1 203 273 8388